GA
ALNY icon

GraniteShares Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

GraniteShares Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Sell
1,620
-135
-8% -$40.7K 0.31% 72
2026
Q1 		$581K Sell
1,755
-31
-2% -$10.5K 0.42% 66
2025
Q4 		$710K Buy
1,786
+147
+9% +$65.1K 0.43% 72
2025
Q3 		$747K Sell
1,639
-260
-14% -$106K 0.43% 68
2025
Q2 		$619K Sell
1,899
-211
-10% -$58.4K 0.38% 72
2025
Q1 		$570K Sell
2,110
-155
-7% -$39.8K 0.36% 71
2024
Q4 		$533K Sell
2,265
-454
-17% -$119K 0.34% 78
2024
Q3 		$748K Sell
2,719
-1,151
-30% -$300K 0.51% 71
2024
Q2 		$940K Buy
3,870
+693
+22% +$109K 0.31% 64
2024
Q1 		$475K Buy
3,177
+387
+14% +$64.6K 0.25% 88
2023
Q4 		$534K Sell
2,790
-103
-4% -$17.5K 0.48% 86
2023
Q3 		$512K Buy
+2,893
New +$552K 0.48% 79
2022
Q1 		– Sell
-595
Closed -$100K – 173
2021
Q4 		$100K Buy
+595
New +$111K 0.05% 270

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GraniteShares Advisors's ALNY Position: Q2 2026 in Review

GraniteShares Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.7% in Q2 2026, selling an estimated $40.7K and leaving 1,620 shares worth $488K. The position accounts for 0.31% of the portfolio, ranked #72.

GraniteShares Advisors first reported a position in ALNY in Q4 2021 and has held it in 13 quarters since. The position peaked at $940K in Q2 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • GraniteShares Advisors held 1,620 shares of Alnylam Pharmaceuticals worth $488K as of Q2 2026.
  • GraniteShares Advisors sold 135 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $40.7K.
  • Alnylam Pharmaceuticals made up 0.31% of GraniteShares Advisors's portfolio in Q2 2026, its #72 holding.
  • GraniteShares Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • GraniteShares Advisors's Alnylam Pharmaceuticals position peaked at $940K in Q2 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on GraniteShares Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.